Skip to content

Clinical trials

Completed Observational Neurologic Manifestations trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neurologic Manifestations Phase: Observational Status: Completed Clear all

76 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20011
20032
20071
20081
20092
20102
20123
20131
20143
20153
20161
20176
20188
20198
20209
20214
20223
20243
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed76

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Neurological Disorders and Stroke (NINDS)5
Vanderbilt University Medical Center5
National Center for Research Resources (NCRR)4
National Heart, Lung, and Blood Institute (NHLBI)4
Akdeniz University2
Ankara Yildirim Beyazıt University2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2
Hikma Pharmaceuticals LLC2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2
Sahlgrenska University Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neurologic Manifestations76
Mental Disorders11
Nervous System Diseases10
Rare Diseases8
Stroke8
Signs and Symptoms7
COVID-196
Cardiovascular Diseases6
Multiple Sclerosis5
Musculoskeletal Diseases4

Trials

Showing 1 to 25 of 76. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.